A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Who May Qualify: - Have Body Mass Index (BMI) at screening of the following: - 30 kilogram per square meter (kg/m2) OR - 27 kg/m2 with at least one of the following weight-related health conditions at screening: - high blood pressure - dyslipidemia - obstructive sleep apnea, or - heart disease - Have a stable body weight (\<5% body weight change) for 90 days prior to screening. - Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight Who Should NOT Join This Trial: - Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) - Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) - Have type 1 diabetes or type 2 diabetes - Have had within 90 days prior to screening: - heart attack - stroke - coronary artery revascularization - unstable angina, or - hospitalization due to congestive heart failure - Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure - Have taken medications or alternative remedies intended for weight loss within 90 days of screening Always talk to your doctor about whether this trial is right for you.